Fabre

Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)

Retrieved on: 
Wednesday, February 8, 2023

From today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets.

Key Points: 
  • From today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets.
  • Pierre Fabre is planning to launch EBVALLO™ in the first European countries during quarter one of 2023.
  • The EC marketing authorization is based on results from the pivotal Phase 3 ALLELE study and additional supportive studies.
  • Atara retains full rights to EBVALLO™ in other major markets, including North America, Asia Pacific, and Latin America.

Bowman Expands in Gulf Coast Through Acquisition of Fabre Engineering, Inc.

Retrieved on: 
Friday, June 3, 2022

Bowman Consulting Group Ltd. (the Company or Bowman) (NASDAQ: BWMN), today announced the purchase of Fabre Engineering, Inc. (Fabre).

Key Points: 
  • Bowman Consulting Group Ltd. (the Company or Bowman) (NASDAQ: BWMN), today announced the purchase of Fabre Engineering, Inc. (Fabre).
  • Frank and the extended Fabre team have a long history in the Gulf Coast, said Gary Bowman, CEO of Bowman.
  • Theres a significant amount of synergy between Fabre and Bowman, said Frank Fabre, founder, and President of Fabre.
  • The Company expects the Fabre acquisition to initially contribute approximately $1.5 million of annualized net service billing.

South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology

Retrieved on: 
Tuesday, July 6, 2021

These antibodies have been functionally validated by the Pierre Fabre R&D teams for their specific properties on a pivotal immuno-oncology target acting on the tumoral microenvironment.

Key Points: 
  • These antibodies have been functionally validated by the Pierre Fabre R&D teams for their specific properties on a pivotal immuno-oncology target acting on the tumoral microenvironment.
  • Pierre Fabre intends to select a new therapeutic candidate in immuno-oncology for further developments.
  • This licensing agreement results from the strong and now proven complementarity between the two companies who have been collaborating since 2018.
  • Young Woo Park, CEO of Y-Biologics,stated: "We are very pleased to sign our first license agreement with Pierre Fabre.

South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology

Retrieved on: 
Tuesday, July 6, 2021

These antibodies have been functionally validated by the Pierre Fabre R&D teams for their specific properties on a pivotal immuno-oncology target acting on the tumoral microenvironment.

Key Points: 
  • These antibodies have been functionally validated by the Pierre Fabre R&D teams for their specific properties on a pivotal immuno-oncology target acting on the tumoral microenvironment.
  • Pierre Fabre intends to select a new therapeutic candidate in immuno-oncology for further developments.
  • This licensing agreement results from the strong and now proven complementarity between the two companies who have been collaborating since 2018.
  • Young Woo Park, CEO of Y-Biologics,stated: "We are very pleased to sign our first license agreement with Pierre Fabre.

License and Commercialization agreement between Pierre Fabre and ValenzaBio on an anti-IGF-1R antibody for the development of a novel treatment in Thyroid Eye Disease (TED)

Retrieved on: 
Thursday, April 8, 2021

In parallel, Pierre Fabre is pursuing the development of its anti-IGF-1R ADC program (W0101) in oncology.

Key Points: 
  • In parallel, Pierre Fabre is pursuing the development of its anti-IGF-1R ADC program (W0101) in oncology.
  • Based on these properties, this monoclonal antibody has the potential to be the best in class product for the treatment of TED.
  • ValenzaBio has demonstrated an ability to apply thoughtful clinical and regulatory strategies to take oncology drugs into autoimmune and inflammatory settings.
  • Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.

Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China

Retrieved on: 
Thursday, February 25, 2021

The amended agreement extends Pierre Fabres commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.

Key Points: 
  • The amended agreement extends Pierre Fabres commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.
  • Concomitantly, Puma and CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing drug candidates in China and North Asia, have mutually agreed to terminate the license agreement to commercialize NERLYNX (neratinib) in Greater China.
  • Alan H. Auerbach, Chief Executive Officer and President of Puma, said, We are pleased to extend our collaboration with Pierre Fabre into the Greater China region.
  • Pierre Fabre is well equipped with existing infrastructure to make NERLYNX a success in mainland China and Pierre Fabre plans to make NERLYNX available to breast cancer patients in mainland China in the second quarter of this year.

The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention

Retrieved on: 
Monday, December 14, 2020

According to the terms of the agreement, EspeRare and the Pierre Fabre Group will pool their respective expertise together in order to co-develop ER-004.

Key Points: 
  • According to the terms of the agreement, EspeRare and the Pierre Fabre Group will pool their respective expertise together in order to co-develop ER-004.
  • The Pierre Fabre group will be granted exclusive worldwide rights for the development, manufacturing and commercialization of ER-004.
  • "At EspeRare we are thrilled to collaborate with the Pierre Fabre Group to co-develop this very inspiring program.
  • 86% of the Pierre Fabre group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan.

The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention

Retrieved on: 
Monday, December 14, 2020

According to the terms of the agreement, EspeRare and the Pierre Fabre Group will pool their respective expertise together in order to co-develop ER-004.

Key Points: 
  • According to the terms of the agreement, EspeRare and the Pierre Fabre Group will pool their respective expertise together in order to co-develop ER-004.
  • The Pierre Fabre group will be granted exclusive worldwide rights for the development, manufacturing and commercialization of ER-004.
  • "At EspeRare we are thrilled to collaborate with the Pierre Fabre Group to co-develop this very inspiring program.
  • 86% of the Pierre Fabre group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan.

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

Retrieved on: 
Monday, November 9, 2020

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ --Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams.

Key Points: 
  • TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ --Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams.
  • Pierre Fabre is a French health and beauty care company with 35-year experience in innovation, development, manufacturing and commercialization in oncology.
  • In 2019, Pierre Fabre generated 2.4 billion euros in revenues, of which two-thirds originated from its international business.
  • Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

Retrieved on: 
Monday, November 9, 2020

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ --Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams.

Key Points: 
  • TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ --Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams.
  • Pierre Fabre is a French health and beauty care company with 35-year experience in innovation, development, manufacturing and commercialization in oncology.
  • In 2019, Pierre Fabre generated 2.4 billion euros in revenues, of which two-thirds originated from its international business.
  • Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.